Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Valeant Pharmaceuticals International headquarters in Mississauga on Wednesday, March 30, 2011. (Norm Betts/Bloomberg)
Valeant Pharmaceuticals International headquarters in Mississauga on Wednesday, March 30, 2011. (Norm Betts/Bloomberg)

Who's Buying and Selling

Insiders still see value at Valeant Add to ...

Valeant Pharmaceuticals International Inc. is up more than 50 per cent in 2011. The winning streak took a hit in August when shares plunged after second-quarter earnings. However, insiders bought heavily. In particular, CEO J. Michael Pearson purchased 155,642 shares. While the stock has regained ground over the past few weeks, we continue to see insider buying. On Nov. 17, which was two weeks after third quarter earnings were released, executive vice-president Brian Stolz bought 2,400 shares. The company trades in both New York and Toronto. Generally, it is encouraging to see insider buying after news.

More related to this story



Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.

Follow on Twitter: @TedDixon

In the know

Most popular video »

Highlights

More from The Globe and Mail

Most Popular Stories